DelveInsight Business Research, LLP: Global Medical Dynamometers Market to Witness Upsurge in Growth at a CAGR of ~6% by 2030 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Personalized Stem Cells Announces First Patients Treated in COVID-19 Clinical Trial Licensed to Sorrento Therapeutics
Personalized Stem Cells, Inc. announces first patients treated in COVID-19 FDA approved stem cell clinical trial licensed to Sorrento Therapeutics.
POWAY, CALIFORNIA, US, February 3, 2021 /EINPresswire.com/ Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, announces that the first patients have received stem cell therapy for the treatment of COVID-19 as part of an FDA approved clinical trial. The ongoing clinical trial and stem cell platform, which PSC developed and then licensed to Sorrento Therapeutics (Nasdaq: SRNE, Sorrento ), is being conducted at UCSF Fresno. The objective of this non-randomized, Phase 1b study is to evaluate the safety and preliminary efficacy of adipose-derived stem cell therapy for the treatment of acute respiratory distress syndrome (ARDS) resulting from infection with COVID-19.